Health Care [ 12/12 ] | Health Care Equipment & Supplies [ 43/74 ]
NYSE | Common Stock
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.
The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name.
The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments.
The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products.
The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system.
The company was founded in 1949 and is headquartered in Galway, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 23, 24 | 1.46 Decreased by -7.01% | 1.45 Increased by +0.69% |
| Feb 20, 24 | 1.30 Increased by 0.00% | 1.26 Increased by +3.17% |
| Nov 21, 23 | 1.25 Decreased by -3.85% | 1.18 Increased by +5.93% |
| Aug 22, 23 | 1.20 Increased by +6.19% | 1.11 Increased by +8.11% |
| May 25, 23 | 1.57 Increased by +3.29% | 1.56 Increased by +0.64% |
| Feb 21, 23 | 1.30 Decreased by -5.11% | 1.27 Increased by +2.36% |
| Nov 22, 22 | 1.30 Decreased by -1.52% | 1.28 Increased by +1.56% |
| Aug 23, 22 | 1.13 Decreased by -19.86% | 1.12 Increased by +0.89% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jul 31, 24 | 7.92 B Increased by +2.77% | 1.04 B Increased by +31.73% | Increased by +13.16% Increased by +28.19% |
| Apr 30, 24 | 8.59 B Increased by +0.53% | 654.00 M Decreased by -44.53% | Increased by +7.61% Decreased by -44.82% |
| Jan 31, 24 | 8.09 B Increased by +4.68% | 1.32 B Increased by +8.18% | Increased by +16.34% Increased by +3.34% |
| Oct 31, 23 | 7.98 B Increased by +5.26% | 909.00 M Increased by +112.88% | Increased by +11.39% Increased by +102.24% |
| Jul 31, 23 | 7.70 B Increased by +4.49% | 791.00 M Decreased by -14.85% | Increased by +10.27% Decreased by -18.51% |
| Apr 30, 23 | 8.54 B Increased by +5.62% | 1.18 B Decreased by -20.61% | Increased by +13.80% Decreased by -24.83% |
| Jan 31, 23 | 7.73 B Decreased by -0.46% | 1.22 B Decreased by -17.43% | Increased by +15.81% Decreased by -17.05% |
| Oct 31, 22 | 7.58 B Decreased by -3.34% | 427.00 M Decreased by -67.43% | Increased by +5.63% Decreased by -66.30% |